Sagapharm SRL
Sagapharm reported total assets of €2.19m at the end of the 2025 financial year (annual accounts filed with the NBB on 29 Sep 2026).
The score of Sagapharm shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +797 % Total assets +768 %
Accounts of the company itself (not consolidated).
The full file covers 5 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Sagapharm's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −19,557 € | ||||
| Equity | 196,807 € | ||||
| Cash | 10,405 € | ||||
| EBITDA | 190,031 € | ||||
| Total assets | €2.19m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 29 Sep 2026
- Year ended 31 Dec 2024filed on 10 Jul 2025
- Year ended 31 Dec 2023filed on 30 Aug 2024
- Year ended 31 Dec 2022filed on 29 Jun 2023
- Year ended 31 Dec 2021filed on 31 Aug 2022
Sagapharm's financial analysis
- Solvency9.0%sector median: 18.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Sagapharm
Sagapharm's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0748.644.218
- VAT number
- BE0748644218
- Peppol
- Registered · 0208:0748644218 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 17 Jun 2020
- Registered office
- 4217 Héron
- Latest accounts
- 2025 · filed on 29 Sep 2026
- Activity
- Buying and selling of own real estate (NACE 68110)
Sagapharm (SRL) has been based in Héron since 2020, active in: buying and selling of own real estate. For 2025, it reports a net loss of 19,557 € and equity of 196,807 €; its revenue is not published. Its solvency stands at 9.0%, below the median of its sector (18.4%).
Companies similar to Sagapharm
Companies in the same business, of comparable size and area, outside its group.
- Steengoed Intermediation service activities for real estate activities Leuven · balance sheet €1.72m
- Herve Lebrun Buying and selling of own real estate Wanze · balance sheet 115,082 €
- Binolux Buying and selling of own real estate Kuurne · balance sheet €1.85m
- Confort Immo Buying and selling of own real estate Binche · balance sheet €1.27m
- RP Investments Buying and selling of own real estate Heusden-Zolder · balance sheet €1.79m
- Living Home Invest Buying and selling of own real estate Forest · balance sheet €2.69m
- Restimmo Buying and selling of own real estate Uccle · balance sheet €1.31m
- Hooom Buying and selling of own real estate Zedelgem · balance sheet €1.48m
Frequently asked questions about Sagapharm
What is the revenue of Sagapharm?
Sagapharm files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Sagapharm?
In Belgium, the VAT number is the company number prefixed with BE: BE0748644218 for Sagapharm, if the company is VAT-registered. Its company number (CBE) is 0748.644.218.
Where is the registered office of Sagapharm?
According to the CBE register, the registered office of Sagapharm is in 4217 Héron.
What is the equity of Sagapharm?
At the close of the 2025 financial year, the equity of Sagapharm amounts to 196,807 €, a solvency of 9.0% of total assets.
Who manages Sagapharm?
The register lists 1 active mandates at Sagapharm. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Sagapharm
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →